This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Ajou University Industry-Academic Cooperation Foundation. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Innovations of Yang-Seon Choi in Therapeutic Compounds
Introduction
Yang-Seon Choi is a notable inventor based in Suwon, South Korea. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target specific signaling pathways in the immune system. His work is crucial for advancing therapeutic options for autoimmune diseases.
Latest Patents
Yang-Seon Choi holds a patent for a small molecule compound that inhibits the signal transmission path of TLR7 and TLR9. This compound, described as a chemical formula, is designed to block the toll-like receptor (TLR) signaling pathway. The innovative compound effectively reduces TNF-α secretion by inhibiting the expression and activation of NF-κB- and MAPK-related proinflammatory genes. This mechanism positions the compound as a potential therapeutic agent for various autoimmune diseases, including systemic lupus erythematosus, psoriasis, and psoriatic arthritis.
Career Highlights
Yang-Seon Choi is affiliated with the Ajou University Industry-Academic Cooperation Foundation, where he continues to engage in research and development. His work is characterized by a strong focus on the intersection of academic research and practical applications in the pharmaceutical industry.
Collaborations
Throughout his career, Yang-Seon Choi has collaborated with esteemed colleagues, including Sangdun Choi and Mahesh Chandra Patra. These collaborations have enhanced the scope and impact of his research, fostering innovation in therapeutic solutions.
Conclusion
Yang-Seon Choi's contributions to the field of pharmaceutical sciences exemplify the importance of innovative research in developing new treatments for autoimmune diseases. His patented compound represents a significant advancement in targeting immune signaling pathways, showcasing the potential for improved therapeutic strategies.